A Randomized, Parallel Group, Open-label, Multicenter Study to Investigate the Efficacy and Safety of Oral BAY85-3934 and Active Comparator (Epoetin Alfa / Beta) in the Maintenance Treatment of Subjects With Anemia Associated With Chronic Kidney Disease Who Are on Dialysis and on Treatment With an Erythropoiesis-stimulating Agent in the United States and Japan
Phase of Trial: Phase II
Latest Information Update: 23 Sep 2019
Price : $35 *
At a glance
- Drugs Molidustat (Primary) ; Epoetin alfa; Epoetin alfa; Epoetin beta; Epoetin beta
- Indications Anaemia
- Focus Therapeutic Use
- Acronyms DIALOGUE4
- Sponsors Bayer
- 11 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 15 Oct 2015 Planned primary completion date changed from 1 Jan 2016 to 1 Oct 2015 as reported by ClinicalTrials.gov.
- 15 Oct 2015 Planned End Date changed from 1 Mar 2016 to 1 Dec 2015 as reported by ClinicalTrials.gov.